Tong Ren Tang Subsidiary Posts Lower 2025 Profit as Revenue and Margins Decline

Tong Ren Tang Technologies Co ( (HK:1666) ) has provided an update.

Tong Ren Tang Technologies reported that its subsidiary Beijing Tong Ren Tang Chinese Medicine Company Limited posted lower revenue and profit for 2025, with sales falling to HK$1.51 billion from HK$1.61 billion and profit attributable to owners dropping to HK$397.2 million from HK$500.3 million. The decline was driven by reduced gross profit, higher impairment losses on financial assets, and weaker contributions from equity-accounted investments, though the group also trimmed distribution and administrative expenses, suggesting efforts to manage costs amid a more challenging operating environment.

The subsidiary’s consolidated gross profit decreased to HK$925.6 million from HK$1.07 billion, and basic earnings per share slipped to HK$0.47 from HK$0.60 year-on-year. These results indicate margin pressure and softer demand compared with 2024, which may weigh on Tong Ren Tang Technologies’ consolidated performance and signal a more cautious outlook for investors tracking the traditional Chinese medicine sector’s growth trajectory.

The most recent analyst rating on (HK:1666) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Tong Ren Tang Technologies Co stock, see the HK:1666 Stock Forecast page.

More about Tong Ren Tang Technologies Co

Tong Ren Tang Technologies Co. Ltd. operates in the traditional Chinese medicine industry through its subsidiary Beijing Tong Ren Tang Chinese Medicine Company Limited, which is listed in Hong Kong. The group focuses on manufacturing and selling Chinese medicine products in domestic and overseas markets, positioning itself as a key player in branded herbal remedies and healthcare formulations.

Average Trading Volume: 1,124,023

Technical Sentiment Signal: Sell

Current Market Cap: HK$5.3B

See more insights into 1666 stock on TipRanks’ Stock Analysis page.